AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%
Last update at 2024-04-24T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -355.72200M | -281.31000M | -284.70900M | -159.42900M | -139.56800M |
| Minority interest | - | - | - | - | - |
| Net income | -356.42200M | -286.82400M | -282.08900M | -156.21700M | -142.56800M |
| Selling general administrative | 4.24M | 28.31M | 149.74M | 62.01M | 53.86M |
| Selling and marketing expenses | 183.10M | 166.42M | 2.10M | - | - |
| Gross profit | 80.90M | 54.39M | 10.56M | 0.41M | 3.73M |
| Reconciled depreciation | 27.85M | 19.85M | 10.25M | 2.91M | 1.73M |
| Ebit | -272.16900M | -274.67600M | -273.16200M | -164.45900M | -141.11000M |
| Ebitda | -241.61200M | -261.11000M | -263.35500M | -159.23000M | -139.38400M |
| Depreciation and amortization | 30.56M | 13.57M | 9.81M | 5.23M | 1.73M |
| Non operating income net other | - | -0.36100M | 3.60M | 5.03M | 3.11M |
| Operating income | -272.16900M | -274.67600M | -273.16200M | -164.45900M | -142.63400M |
| Other operating expenses | 404.73M | 352.47M | 288.49M | 164.87M | 146.36M |
| Interest expense | 16.47M | 6.27M | 15.15M | 0.00000M | 0.04M |
| Tax provision | 0.70M | 0.00000M | -2.62000M | 0.00000M | 3.00M |
| Interest income | 4.89M | 0.34M | 4.32M | 5.53M | 4.02M |
| Net interest income | -11.58300M | -5.93600M | -10.82600M | 5.53M | 3.98M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.70M | 5.51M | -2.62000M | -3.21200M | 3.00M |
| Total revenue | 132.56M | 77.80M | 15.32M | 0.41M | 3.73M |
| Total operating expenses | 353.07M | 329.06M | 283.72M | 164.87M | 146.36M |
| Cost of revenue | 51.67M | 23.41M | 4.77M | - | 0.00000M |
| Total other income expense net | -83.55300M | -6.63400M | -11.54700M | 5.03M | -0.91300M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -356.42200M | -281.31000M | -282.08900M | -159.42900M | -142.56800M |
| Net income applicable to common shares | -356.42200M | -281.31000M | -282.08900M | -159.42900M | -142.56800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 581.90M | 531.16M | 720.22M | 340.29M | 226.35M |
| Intangible assets | 27.00M | 55.33M | 71.34M | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.36M | 7.54M | 5.79M | 6.49M | 5.11M |
| Total liab | 569.30M | 462.69M | 345.93M | 114.80M | 80.73M |
| Total stockholder equity | 12.60M | 68.47M | 374.29M | 225.49M | 145.62M |
| Deferred long term liab | - | - | - | - | 6.07M |
| Other current liab | 59.36M | 42.58M | 36.02M | 21.59M | 0.54M |
| Common stock | 0.08M | 0.07M | 0.07M | 0.05M | 0.04M |
| Capital stock | 0.08M | 0.07M | 0.07M | 0.05M | 0.04M |
| Retained earnings | -1754.37400M | -1397.95200M | -1126.29300M | -844.20400M | -684.77500M |
| Other liab | 80.06M | 75.64M | 77.29M | 47.95M | 48.76M |
| Good will | 77.17M | 146.96M | 146.96M | - | - |
| Other assets | 35.24M | 13.75M | 4.78M | 2.40M | 3.98M |
| Cash | 108.97M | 110.62M | 333.56M | 171.16M | 73.26M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 75.68M | 67.29M | 60.96M | 40.98M | 31.97M |
| Current deferred revenue | 6.87M | 9.36M | 7.85M | 7.91M | 8.59M |
| Net debt | 309.50M | 213.89M | -121.44900M | -141.82000M | -73.25600M |
| Short term debt | 4.91M | 4.75M | 4.44M | 3.47M | 14.41M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 418.47M | 324.51M | 212.11M | 29.34M | - |
| Other stockholder equity | 1767.27M | 1466.37M | 1500.51M | 1069.64M | 830.37M |
| Property plant equipment | 67.75M | 69.00M | 17.50M | 14.76M | 14.45M |
| Total current assets | 374.73M | 246.12M | 450.00M | 296.60M | 207.92M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -91.57900M | -133.82700M | 155.98M | 225.49M | 145.62M |
| Short term investments | 231.74M | 114.45M | 102.95M | 118.95M | 102.56M |
| Net receivables | 11.34M | 3.35M | 1.83M | 0.00000M | 27.00M |
| Long term debt | 379.37M | 280.63M | 180.53M | - | - |
| Inventory | 18.32M | 10.15M | 5.88M | - | - |
| Accounts payable | 4.55M | 10.60M | 12.66M | 8.01M | 8.43M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.37400M | -0.01800M | - | 0.00300M | -0.00800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.07M | 0.07M | 0.05M | 0.04M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -1397.95200M | -1126.29300M | -844.20400M | -684.77500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 35.24M | 13.75M | 4.78M | 2.40M | 3.98M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 207.17M | 285.05M | 270.22M | 43.69M | 18.43M |
| Capital lease obligations | 39.09M | 43.88M | 31.58M | 29.34M | 0.00000M |
| Long term debt total | - | 280.63M | 180.53M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -138.79800M | -11.59000M | 272.37M | -14.36200M | -101.47600M |
| Change to liabilities | -3.51800M | -3.45500M | 17.91M | 3.21M | 3.30M |
| Total cashflows from investing activities | -138.79800M | -29.66500M | 12.13M | -17.59200M | -107.02600M |
| Net borrowings | 87.05M | 87.05M | 249.44M | -0.74200M | -1.29800M |
| Total cash from financing activities | 331.69M | 29.87M | 331.48M | 221.66M | 1.78M |
| Change to operating activities | 18.18M | 4.48M | 13.87M | 3.04M | -3.29400M |
| Net income | -356.42200M | -281.31000M | -282.08900M | -159.42900M | -142.56800M |
| Change in cash | -0.65200M | -221.33400M | 165.11M | 97.90M | -209.49000M |
| Begin period cash flow | 115.67M | 337.00M | 171.89M | 73.99M | 283.48M |
| End period cash flow | 115.02M | 115.67M | 337.00M | 171.89M | 73.99M |
| Total cash from operating activities | -193.54800M | -221.53800M | -178.50200M | -106.16100M | -104.24600M |
| Issuance of capital stock | 248.01M | 21.71M | 83.95M | 222.84M | 0.00000M |
| Depreciation | 39.15M | 19.85M | 10.25M | 2.91M | 1.73M |
| Other cashflows from investing activities | -19.80000M | -7.70000M | -0.93600M | 0.00800M | 1.44M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -6.00800M | -4.27800M | -5.87600M | -27.00000M | -3.17300M |
| Change to account receivables | -7.99000M | -1.51900M | 12.14M | 27.00M | -26.95200M |
| Sale purchase of stock | - | 38.05M | 74.90M | 11.81M | 5.29M |
| Other cashflows from financing activities | 94.78M | 8.16M | 247.54M | -1.18300M | 2.71M |
| Change to netincome | 121.18M | 43.44M | 46.78M | 18.72M | 14.98M |
| Capital expenditures | 23.01M | 18.07M | 4.22M | 3.24M | 7.09M |
| Change receivables | - | -1.51900M | -1.73600M | 27.00M | -26.95200M |
| Cash flows other operating | - | -5.46300M | 26.95M | 4.07M | 46.37M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -221.33400M | 165.11M | 97.90M | -209.49000M |
| Change in working capital | 0.67M | -4.77400M | 39.97M | 34.27M | 22.72M |
| Stock based compensation | 52.34M | 43.43M | 36.45M | 17.92M | 16.27M |
| Other non cash items | 70.72M | 1.17M | 19.63M | 0.81M | 0.17M |
| Free cash flow | -216.55800M | -239.61300M | -182.71800M | -109.39900M | -111.33700M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RVNC Revance The |
-0.09 2.46% | 3.57 | - | - | 3.11 | 12.30 | 3.98 | -2.5297 |
| NVO Novo Nordisk A/S |
-2.48 1.93% | 126.16 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.58 1.23% | 126.80 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.15 1.02% | 400.76 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
-0.61 0.67% | 90.10 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
1222 Demonbreun Street, Nashville, TN, United States, 37203
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark J. Foley | CEO & Director | 1965 |
| Mr. Dustin S. Sjuts | Pres | 1979 |
| Mr. Tobin C. Schilke | CFO & Principal Accounting Officer | 1975 |
| Mr. Aubrey Rankin | Consultant | 1976 |
| Jessica Serra | Head of Investor Relations & ESG | NA |
| Mr. Dwight Moxie | Sr. VP, Gen. Counsel & Corp. Sec. | 1977 |
| Ms. Jeanie D. Herbert | Sr. Director of Investor Relations & Corp. Communications | NA |
| Ms. Taryn Conway | VP of Marketing | NA |
| Mr. Justin Ford | Sr. VP of HR & Head of People | NA |
| Ms. Azita Nejad | Sr. VP of Technical Operations | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...